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Rheumatic diseases are very prevalent, affecting about 7 million people in North America; they affect the
musculoskeletal system, often with systemic involvement and potential for serious consequences and limitation
on quality of life. Clinical treatment is usually long-term and includes drugs that are considered either simple
or complex and are occasionally unknown to many health professionals who do not know how to manage
these patients in emergency units and surgical wards. Thus, it is important for clinicians, surgeons and
anesthesiologists who are involved with rheumatic patients undergoing surgery to know the basic principles of
therapy and perioperative management. This study aims to do a review of the perioperative management of
the most commonly used drugs in rheumatologic patients. Manuscripts used in this review were identified by
surveying MEDLINE, LILACS, EMBASE, and COCHRANE databases and included studies containing i) the peri-
operative management of commonly used drugs in patients with rheumatic diseases: and ii) rheumatic diseases.
They are didactically discussed according to the mechanism of action and pharmacokinetics; and perioperative
management. In total, 259 articles related to the topic were identified. Every medical professional should be
aware of the types of drugs that are appropriate for continuous use and should know the various effects of
these drugs before indicating surgery or assisting a rheumatic patient postoperatively. This information could
prevent possible complications that could affect a wide range of patients.
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’ INTRODUCTION
Rheumatic diseases are very prevalent, affecting about
7 million people in North America (1); they affect the muscu-
loskeletal system, often with systemic involvement and
potential for serious consequences and limitation on quality
of life (2,3). The diagnoses of such diseases are not simple and
may require additional tests and multidisciplinary approaches
(4). Clinical treatment is usually long-term, using drugs that
are considered either simple or complex and are occasionally
unknown to many health professionals. Such a lack of under-
standing could lead to difficulty in managing these patients in
primary care services, emergency units and surgical wards (4).
An estimated 33 million patients undergo surgical pro-
cedures each year in the United States. Serious adverse events
occur in more than 1 million of these patients at an annual
estimated cost of US$ 25 billion. With an aging population, it is
expected that surgical indications and surgical costs will
increase by 25% and 50%, respectively, and that the cost of
perioperative complications will double (5).
The incidence of postoperative infections ranges from 0.5
to 6.0%, depending on the medical center, the type of surgery,
and the surgical site (6). Rheumatic patients, however, are at
increased risk of developing postoperative infections. Appro-
ximately 25% of all patients with rheumatoid arthritis will
require surgery within the first 20 years of disease, excluding
emergency procedures not related to preexisting maladies.
The major complication of elective orthopedic procedures is
surgical site infection, with an incidence between 2-15% and
the drugs used by these patients cannot be ruled out as a
contributing factors to such high rates (7–11).
Considering the epidemiology of such diseases and pro-
fessional accountability for the use of prescribed drugs, it is
imperative that clinicians, surgeons and anesthesiologists
who are involved with rheumatic patients undergoing sur-
gery know the basic principles of drug therapy and peri-
operative management (12–14).
The purpose of the present study is to evaluate the drugs that
are most commonly used in patients with rheumatic diseases
and to guide the perioperative management of these drugs.
’ METHODS
Manuscripts used in this review were identified by
surveying MEDLINE, LILACS, EMBASE, and COCHRANEDOI: 10.6061/clinics/2017(06)09
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databases and included studies containing i) the periopera-
tive management of commonly used drugs in patients with
rheumatic diseases: nonsteroidal anti-inflammatory drugs,
glucocorticoids, disease-modifying antirheumatic drugs and
biological drugs; and ii) rheumatic diseases: Behc¸et Syn-
drome, Dermatomyositis, Gout, Juvenile Arthritis, Mixed
Connective Tissue Disease, Polymyalgia Rheumatica, Rheu-
matic Fever, Rheumatoid Arthritis, Sjogren’s Syndrome,
Spondyloarthropathies, Still’s Disease, Systemic Lupus Ery-
thematosus, Systemic Scleroderma, and Vasculitis.
There were no time or language restrictions and the last
search dates back from 30 April 2016 for all databases.
Articles discussing bone metabolism and cardiovascular
events were excluded.
Initially, throughout all the data from the selected articles,
we sought for (1) the rheumatic disease(s) each of them
studied; (2) the drugs used by the patients; (3) the type of
surgery; and (4) the perioperative management. Finally, we
extracted the results of each article and organized them accord-
ing to these aforementioned four items.
The selected items and results are discussed in this review
according to the following breakdown:
 mechanism of action and pharmacokinetics of the main
drugs used to control rheumatic diseases;
 perioperative management of the commonly used drugs in
patients with rheumatic diseases.
’ RESULTS
The search of MEDLINE, EMBASE, LILACS and
COCHRANE databases provided 237 studies. After remov-
ing the duplicates, 223 remained. Of these, 18 studies were
not full text; and 172 were discarded because after reviewing
the abstracts these papers clearly did not meet the eligibility
criteria. Twelve additional studies that met the criteria for
inclusion were identified by checking the references of other
relevant papers that did not meet our criteria. The full texts
of the remaining 45 citations were examined in more detail.
No unpublished relevant studies were obtained. 6 articles
were not used in this review based on our exclusion criteria.
It is also important to note the lack of randomized, double-
blind researches/trials comparing the safety of drugs in
rheumatic diseases in emergency procedures and not only in
elective surgeries.
In our review, we only found articles about rheumatoid
arthritis, systemic lupus erythematosus and osteoarthritis,
excluding any other rheumatic diseases. Regarding the treat-
ment and perioperative management of such conditions, we
found information on Nonsteroidal antiinflammatory drugs
and aspirin (NSAIDs), glucocorticoids, Disease-modifying
antirheumatic drugs (DMARDs) and biological drugs, pre-
sented as follows.
Aspirin and Nonsteroidal anti-inflammatory drugs
(NSAIDs)
The inhibition of COX-1 by aspirin and other NSAIDs
results in increased bleeding time. This effect is lasting due to
the inhibition of platelet COX and it is reversed only after drug
withdrawal, which is considered to be effective after 4 to 5
half-lives. Thus, it is important to remember that depending
on the average half-life of a particular NSAID, it should be
suspended for hours or even days before surgical procedure.
Regarding COX-2 inhibitors, drugs that have minimal
effects on platelet function (15), withdrawal during the
perioperative period is not required (Table 1).
For patients who are in need of continuing aspirin treat-
ment to manage the risk of thromboembolism / ischemia, no
changes in dosage are indicated because the cardiovascular
risk outweighs the intraoperative benefits of altering the
drug intake (16–18). In such cases, the surgeon must be aware
of this condition and be prepared for bleeding complications
during the intraoperative period (19–22). Although Tytgat
et al. (23) did not show differences in surgeons’ assessment
of intraoperative bleeding in carotid endarterectomy among
patients who stopped aspirin before surgery and those who
continued aspirin intake. In fact, postoperative complications
like hematomas were not significantly increased, even in sur-
geries including cholecystectomy, appendectomy, open or
laparoscopic inguinal hernia repair, liver surgery and hip
and knee arthroscopy (16,24,25). Current guideline suggests to
not withdraw aspirin for secondary cardiovascular prevention
before surgeries (19).
Considering rheumatic patients, the use of NSAIDs is
indicated to prevent heterotopic ossification after arthro-
plasty, especially in patients with ankylosing spondylitis and
psoriatic arthritis, for whom Indomethacin (75-100 mg/day)
or Celecoxib (400 mg/day) are recommended before the fifth
postoperative day, optimally within 24 to 48 hours, for 20
days after surgery (22,26,27).
Glucocorticoid prescription due to Hypothalamic-
Pituitary-Adrenal axis suppression
Hypothalamic-pituitary-adrenal axis suppression occurs in
patients who are on chronic use of glucocorticoids. If the
doses are above the physiologic range (10-12 mg of cortisol/
day), 30 days is probably the minimal for inhibition of
endogenous glucocorticoid synthesis. There is evidence that
the use of 20 mg of prednisone for 5 days is already sufficient
to inhibit cortisol synthesis (28). In such cases, it is necessary
to supplement the glucocorticoid dose in the perioperative
period due to surgical stress, even with the increased risk of
infection and hindering of wound healing induced by these
drugs (29,30) (Table 2).
A decade ago, high doses of corticosteroids were given
to patients with adrenal insufficiency before surgery. More
recent studies prefer to assess therapy length, corticosteroid
Table 1 - Nonsteroidal anti-inflammatory drugs.
NSAID Half-life (hours) Withdrawal before surgery
Naproxen 12-15 3 days
Ibuprofen 1.6-1.9 10 hours
Diclofenac 2 10 hours
Indomethacin 4.5 1 day
COX-2 inhibitor (Celecoxib) 11 maintain usual dosage
Adapted from reference 21.
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dose and degree of surgical stress to prescribe the minimum
amount of drug (31) (Table 2). An ACTH stimulation test
could be performed during preoperative evaluation to verify
the need for corticosteroid supplementation (32), although the
low sensitivity observed in patients with secondary adrenal
insufficiency frequently requires additional testing (33).
Disease-modifying antirheumatic drugs
Disease-modifying antirheumatic drugs (DMARDs) are
a heterogeneous group of drugs and their main benefit is
to delay the progression of some rheumatologic diseases
by changing its natural history. Most prospective and
retrospective studies have suggested that methotrexate and
other DMARDs may be continued during the perioperative
period without compromising healing or increasing the risk
of infection (12,34).
Hydroxychloroquine in lupus patients, reduces disease
activity, cardiovascular risk, insulin resistance, thromboem-
bolic events, infection risk and mortality (35–38), and this
drug should not be discontinued during the perioperative
period.
Table 3 summarizes the half-life, mechanism of action,
side effects and management regarding the perioperative
period.
Table 2 - Glucocorticoid prescription according to surgical aggression.
Type of surgery / surgical stress Surgical Procedures Glucocorticoid prescription
Superficial procedure
(anesthesia o1 hour)
Ophthalmologic surgeries,
herniorrhaphy
Not necessary.
Maintain daily dosage.
Small surgical stress Carpal tunnel release, colonoscopy,
knee arthroscopy
25 mg hydrocortisone IV or 5 mg methylprednisolone IV
on the procedure day
Mild surgical stress hip arthroplasty, knee arthroplasty,
laparoscopic abdominal surgery, pulmonary biopsy
50-75 mg hydrocortisone IV or 10-15 mg methylprednisolone
IV on the procedure day
Important surgical stress bilateral hip arthroplasty, total ankle arthroplasty,
spine surgery, open abdominal surgery,
hysterectomy
100-150 mg hydrocortisone IV or 30 mg methylprednisolone
IV on the procedure day; return to previous dosage by
lowering it on the next 1 to 2 days
Adapted from references 14 and 34.
Table 3 - DMARDs - mechanism of action, half-life and management in the perioperative period.
Drug Half-life Mechanism of action Management
Methotrexate 3-10 hours Dihydrofolate reductase inhibition Maintain usual dosage*
Hydroxychloroquine 32-50 hours Lysosomal membrane stabilization and
reduces IL-1 and TNF synthesis
Maintain usual dosage
Leflunomide 2 weeks Pyrimidine synthesis inhibitor -
lowers B and T cell population
Withdraw 2 weeks before surgery;
resume after 3 days (controversial)
Ciclosporin 5-18 hours Inhibits T cell activation by inhibiting
calcineurin – cyclophilin ligand
Withdraw 1 week before and 1 week
after surgery
Azathioprine 1-3 hours Purine synthesis inhibition –
inhibits cell proliferation
Maintain usual dosage
Mycophenolate mofetil 16-18 hours Restricts T and B cell proliferation –
action upon purine-synthesising enzyme
Withdraw 1 week before surgery;
resume 1 to 2 weeks after surgery
* in special situations (Chronic kidney disease, poorly controlled diabetes mellitus, etc.): methotrexate should be suspended one week before.
Adapted from references 12, 34, 39, 40 and 41.
Table 4 - Biological agents - Half-life, mechanism of action, management during perioperative period and major side effects.
Drug Half-life Mechanism of action Management Side effects
Etanercept 3.5 – 5.5 days Anti-TNF Withdraw 10 days
before surgery
Increased risk of infection
Adalimumab 10 – 20 days Withdraw 30 days
before surgery
Infliximab 9.5 days Withdraw 19 days
before surgery
Certolizumab 14 days Withdraw 28 days
before surgery
Golimumab 14 days Withdraw 28 days
before surgery
Abatacept 12.6 days T cell inhibitor Withdraw 25 days
before surgery
Increased risk of infection, headache,
gastrointestinal disorders
Rituximab 18 – 22 days
(effects can last for months)
B cell inhibitor Withdraw 100 days
before surgery
Increased risk of infection, Stevens-Johnson
syndrome, hypotension, arrhythmias
Tocilizumab 11 – 13 days IL-6 receptor
antagonist
Withdraw 26 days
before surgery
Increased risk of infection,
hepatotoxicity
Anakinra 4 – 6 hours IL-1 receptor
antagonist
Withdraw 1 to 2 days
before surgery
Increased risk of infection,
hepatotoxicity
Adapted from reference 34.
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Biological drugs
Biological agents are newer, high cost drugs with specific
mechanisms of action for each molecule - they are antibodies
against a target molecule. Within rheumatology, the main
agents used are those that antagonize TNF, IL-1, IL-6, CD20 and
costimulatory molecules. The mechanism of action, half-life,
management during the perioperative period and main side
effects of each of the various biologic agents are summarized in
Table 4.
For minor procedures, there is no need to interrupt most
of these agents, since there is no evidence of increased risk of
infection or impaired healing of the surgical site (12). How-
ever, for major surgeries, their interruption is recommended
for at least twice their half-lives before surgery and may be
resumed from 10 to 14 days after surgery (9,39–43), since all
of these agents increase the risk of infections. Some drugs, as
rituximab, an anti-CD20 monoclonal antibody that depletes
populations of B lymphocytes, have a longstanding effect,
beginning 2 to 3 weeks after drug introduction and lasting
up to 12 months after withdrawal. Severe hypogammaglo-
binemia is a rare adverse effect of rituximab that could
lead to infections. Serum IgG levels may be assessed prior to
surgery and patients with low values (IgGo 500 mg/L) may
receive intravenous immunoglobulin replacement therapy
(44,45).
More studies are necessary to develop guidelines with
strong evidence about the safety and management of drugs
in the perioperative period in patients with rheumatic
diseases. The differentiation of elective procedures and emer-
gency surgeries would also be an important matter for the
medical community to reduce infections and complications
after surgery.
’ CONCLUSION
Knowing the various drugs used in patients with rheu-
matic diseases is necessary because their side effects can
modify the progression of the postoperative period. Hence,
every physician, before suggesting surgical procedures or
following the postoperative evolution of a rheumatic patient,
should be capable of managing continuous-use drugs. The
most important measures to remember are: a) Aspirin intake
for secondary cardiovascular prevention should be main-
tained during perioperative period for most surgeries;
b) NSAIDs should be suspended for hours or even days accord-
ing to half-life time before surgical procedure; c) Glucocorti-
coid prescription must be made according to surgical stress;
d) Methotrexate, hydroxychloroquine and azathioprine should
be maintained during perioperative period; e) biological
agents are recommended to be suspended 2 half-lives prior
to surgery; f) the administration of such drugs should be
restarted based on clinical status and absence of complications
(infections and bleeding).
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